A new registry analysis suggests transcatheter aortic valve replacement (TAVR) may benefit patients with severe aortic stenosis but only minimal symptoms.
The US Food and Drug Administration has only approved TAVR devices to treat severe, symptomatic aortic stenosis, but about 20%...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?